Literature DB >> 29505880

Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up.

K E Eliassen1, H Reiso2, D Berild3, M Lindbæk4.   

Abstract

OBJECTIVES: To compare the three most commonly used antibiotics for erythema migrans (EM) in Norwegian primary care.
METHODS: A randomized, parallel, controlled trial was carried out. Treatments were open to the patients, but blinded for the GPs and investigators. Patients eligible for inclusion were aged ≥18 years and clinically diagnosed with EM. Block randomization was processed in blocks of six. Patients were assigned to receive one of three antibiotic treatments for 14 days: phenoxymethylpenicillin (PCV), amoxicillin, or doxycycline. The primary outcome was the duration of EM in days in the three treatment groups. Patients kept a diary for the 14 days of treatment, in which they registered concomitant symptoms and side effects. The patients consulted their GP after 14 days of treatment and had a 1-year follow-up to monitor any development of disseminated Lyme borreliosis (LB). EMs with a duration of more than 14 days were followed until resolution. ClinicalTrials.govNCT01368341 and EU Clinical Trials Register 2010-023747-15.
RESULTS: One hundred and eighty eight patients (PCV: n = 56, amoxicillin: n = 64, doxycycline: n = 68) were included by 44 Norwegian general practitioners (GPs) from June 2011 to November 2013. Follow-up was completed by December 2014. The median duration of EM was altogether 14 days (range 3-293). For the PCV group median duration was 14 days (range 5-91), for amoxicillin 13 days (range 4-179) and for doxycycline 14 days (range 3-293). The duration of EM did not differ significantly between the three antibiotic groups (p 0.277). None of the patients developed disseminated LB within the 1-year follow-up.
CONCLUSIONS: We did not find 14 days of PCV, doxycycline, and amoxicillin treatments to differ in effectiveness or safety in the treatment of clinically diagnosed EM in primary care.
Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotics; Early Lyme; Erythema migrans; General practice; Lyme borreliosis; Tick borne diseases

Mesh:

Substances:

Year:  2018        PMID: 29505880     DOI: 10.1016/j.cmi.2018.02.028

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

Review 1.  Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Gerta Rücker; Karin Bischoff; Michael H Freitag; Rick Dersch; Volker Fingerle; Edith Motschall; Joerg J Meerpohl; Christine Schmucker
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

Review 2.  Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Authors:  Vladimir V Bamm; Jordan T Ko; Iain L Mainprize; Victoria P Sanderson; Melanie K B Wills
Journal:  Pathogens       Date:  2019-12-16

3.  Forty Years of Evidence on the Efficacy and Safety of Oral and Injectable Antibiotics for Treating Lyme Disease of Adults and Children: A Network Meta-Analysis.

Authors:  Jiaru Yang; Shiyuan Wen; Jing Kong; Peng Yue; Wenjing Cao; Xin Xu; Yu Zhang; Jingjing Chen; Meixiao Liu; Yuxin Fan; Lisha Luo; Taigui Chen; Lianbao Li; Bingxue Li; Yan Dong; Suyi Luo; Guozhong Zhou; Aihua Liu; Fukai Bao
Journal:  Microbiol Spectr       Date:  2021-11-10

4.  The Norwegian PraksisNett: a nationwide practice-based research network with a novel IT infrastructure.

Authors:  Espen Saxhaug Kristoffersen; Bjørn Bjorvatn; Peder Andreas Halvorsen; Stein Nilsen; Guro Haugen Fossum; Egil A Fors; Pål Jørgensen; Berit Øxnevad-Gundersen; Svein Gjelstad; Johan Gustav Bellika; Jørund Straand; Guri Rørtveit
Journal:  Scand J Prim Health Care       Date:  2022-05-13       Impact factor: 3.147

5.  Doxycycline host-directed therapy in human pulmonary tuberculosis.

Authors:  Qing Hao Miow; Andres F Vallejo; Yu Wang; Jia Mei Hong; Chen Bai; Felicia Sw Teo; Alvin Dy Wang; Hong Rong Loh; Tuan Zea Tan; Ying Ding; Hoi Wah She; Suay Hong Gan; Nicholas I Paton; Josephine Lum; Alicia Tay; Cynthia Be Chee; Paul A Tambyah; Marta E Polak; Yee Tang Wang; Amit Singhal; Paul T Elkington; Jon S Friedland; Catherine Wm Ong
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

Review 6.  Phenoxymethylpenicillin Versus Amoxicillin for Infections in Ambulatory Care: A Systematic Review.

Authors:  Philip Lawrence Skarpeid; Sigurd Høye
Journal:  Antibiotics (Basel)       Date:  2018-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.